1Y Close · As of Aug 26, 2026
Gc Biopharma operates in the Pharmaceuticals sector.
Legal name: GC Biopharma Corp.
In fiscal year 2025, Gc Biopharma (006280) reported revenue of 1.99 trillion KRW, up 18.5% from 1.68 trillion KRW a year earlier.
Operating profit was 69.1 billion KRW and net income was -29.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 1.53 trillion KRW, with a P/B of 1.09.
These figures can be verified in the DART filing (receipt no. 20260318001316).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 2.0T | 69.1B | -29.7B |
| 2024 | 1.7T | 32.1B | -42.6B |
| 2023 | 1.6T | 34.4B | -19.8B |
Recent Filings
Semi-Annual Report (2026.06)
Officer/Major Shareholder Ownership Report
Fair Trade Compliance Status (Informational Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Officer/Major Shareholder Ownership Report |
| 2026-07-31 | Fair Trade Compliance Status (Informational Disclosure) |
| 2026-07-31 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |